Navigation Links
Blood pressure drug telmisartan shows powerful activity against stroke
Date:12/12/2007

NEW YORK (Dec. 12, 2007) -- Telmisartan, a drug widely used to help control blood pressure, may have uniquely potent activity in preventing stroke, according to a new study conducted in an animal model.

Whether they used the drug alone or in combination with a different type of antihypertensive medication, ramipril, Weill Cornell Medical College researchers found that rats fed a high-salt, stroke-inducing diet were completely protected from the brain attacks while on telmisartan.

"No other study has ever shown complete protection against stroke in this rat model using normal human drug doses" notes study senior author Dr. Daniel F. Catanzaro, professor of physiology and biophysics and professor of physiology in cardiothoracic surgery at Weill Cornell Medical College.

The study, which was funded by telmisartan's German maker, Boehringer Ingelheim Pharma GmbH & Co., is published online in the Journal of the American Society of Hypertension.

Telmisartan (brand name Micardis) is one of a class of widely used antihypertensive drugs known as angiotensin receptor blockers (ARBs). "These drugs primarily act on the vasculature to relax the small blood vessels," Dr. Catanzaro explains.

Telmisartan stands out from other ARBs in that its molecular structure allows it to more easily pass through the blood-brain barrier and enter the brain -- something many drugs cannot do.

The new animal study was not constructed to specifically look at telmisartan's effect on stroke. "Because blood pressure is closely related to stroke risk, we really just wanted to look and see if combinations of antihypertensive drugs were better at lowering blood pressure and stroke compared to the use of single agents," Dr. Catanzaro explains.

In this case, his team tested two drugs -- telmisartan and an ACE inhibitor, ramipril (Altace) -- in a rat model long favored by stroke researchers. In this approach, rats are fed what's known as a "stroke-prone diet," meaning they get lots of salt in both their food and water.

"This rat model has been great at showing us the neuroprotective properties of different drugs in the past, and the results usually correlate with results in humans," Dr. Catanzaro says.

In the study, 25 rats were fed the stroke-prone diet for 8 weeks and received either no medication, telmisartan alone, ramipril alone, or the two drugs together at either full- or half-doses.

"A main finding was that combination therapy did reduce blood pressure the best of any treatment, and it also was best at cutting damage to the rats' hearts and kidneys," Dr. Catanzaro says. "But what was really surprising to us was that any regimen involving telmisartan at doses that would normally be given to humans completely prevented stroke in this model. Most studies with other drugs have used much higher doses and have found only partial protection."

Specifically, 83 percent of rats given no medication showed signs of stroke, as did 56 percent of rats given ramipril alone. However, no strokes were noted in the telmisartan-only or the telmisartan/ramipril combo groups.

Telmisartan's ability to easily pass through the blood-brain barrier (something ramipril cannot do) is likely behind the neuroprotective effect noted in the study, the researchers say.

"Going forward, that's something that we would really like to test out in head-to-head trials pitting telmisartan against other ARBs, for example," Dr. Catanzaro said. "At the same time, we'd like to examine whether telmisartan is actually getting into the brain, or if more peripheral effects -- a lowering of blood pressure, for instance -- are behind the reduction in stroke."

In the meantime, Boehringer Ingelheim is nearing the end of a major clinical trial looking at the effectiveness of combining telmisartan with ramipril to lower patients' blood pressures and reduce their odds for heart attack and stroke. Dr. Catanzaro's team is not involved in that study.


'/>"/>

Contact: Andrew Klein
ank2017@med.cornell.edu
212-821-0560
New York- Presbyterian Hospital/Weill Cornell Medical Center/Weill Cornell Medical College
Source:Eurekalert

Related biology news :

1. High blood pressure, low energy -- a recipe for heart failure
2. Right breakfast bread keeps blood sugar in check all day
3. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
4. Folic acid lowers blood arsenic levels, according to Mailman School of Public Health study
5. Folic acid lowers blood arsenic levels in Bangladesh
6. Study reveals a key to blood vessel growth and possible drug target
7. Expecting an afternoon nap can reduce blood pressure
8. MIT: blood may help us think
9. Immune cells promote blood vessel formation in mouse endometriosis
10. Elevated nitric oxide in blood is key to high altitude function for Tibetans
11. Fine-tuning lasers to destroy blood-borne diseases like AIDS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/23/2016)... , March 23, 2016 ... Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung mit ... Inc. (NASDAQ: MESG ), ein ... dass das Unternehmen mit SpeechPro zusammenarbeitet, um ... der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):
(Date:4/28/2016)... ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell counting ... on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, Massachusetts. ...
(Date:4/27/2016)... ... April 27, 2016 , ... Shimadzu Scientific Instruments ... Spring 2016 Marijuana Business Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to ... more. Expo attendees can stop by booth 1021 to learn how Shimadzu’s instruments ...
(Date:4/27/2016)... RESEARCH TRIANGLE PARK, N.C. , April 27, ... ) announced today that Martine Rothblatt , Ph.D., ... provide an overview and update on the company,s business ... Care Conference. The presentation will take place ... Time, and can be accessed via a live webcast ...
(Date:4/27/2016)... Winnipeg, Manitoba (PRWEB) , ... April 27, 2016 ... ... commercially released for simultaneous preclinical PET (Positron Emission Tomography) and MRI (Magnetic Resonance ... for better understanding disease and testing novel treatments in small animal subjects. Simultaneous ...
Breaking Biology Technology: